朗玛信息(300288) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥106,621,778.87, representing a 3.96% increase compared to ¥102,559,778.51 in the same period last year[5] - Net profit attributable to shareholders was ¥21,263,432.84, a significant increase of 39.96% from ¥15,193,039.67 year-on-year[5] - Basic earnings per share rose to ¥0.0629, reflecting a 39.78% increase from ¥0.0450 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 106,621,778.87, an increase of 3.3% compared to CNY 102,559,778.51 in Q1 2022[25] - Net profit for Q1 2023 reached CNY 20,681,420.89, up 56.5% from CNY 13,184,313.84 in the same period last year[26] - Earnings per share (EPS) increased to CNY 0.0629 from CNY 0.0450, representing a growth of 39.1%[27] - The total comprehensive income attributable to shareholders of the parent company was CNY 21,263,432.84, compared to CNY 15,193,039.67 in the previous year, an increase of 40.0%[27] Cash Flow and Investments - The net cash flow from operating activities surged by 224.49%, reaching ¥10,517,895.97, compared to ¥3,241,332.11 in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 10,517,895.97, significantly higher than CNY 3,241,332.11 in Q1 2022[28] - The net cash flow from investment activities was -6,219,657.75 CNY, indicating a significant outflow compared to the previous period's -671,698.46 CNY[29] - Cash flow from financing activities showed a net outflow of -668,376.39 CNY, compared to -101,378,831.95 CNY in the previous period[29] - The net increase in cash and cash equivalents for the quarter was 3,629,861.83 CNY, contrasting with a decrease of -98,809,198.30 CNY in the prior period[29] - The ending balance of cash and cash equivalents was 335,159,684.00 CNY, up from 283,021,459.56 CNY at the end of the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,867,402,037.41, a slight increase of 0.98% from ¥1,849,235,259.72 at the end of the previous year[5] - Total liabilities decreased to ¥285,871,594.45 from ¥288,386,237.65, a reduction of approximately 0.5%[23] - The company’s non-current assets totaled ¥1,430,903,265.00, slightly up from ¥1,427,674,436.02, reflecting a marginal increase[22] - The company’s equity remained stable at ¥337,941,402.00, unchanged from the beginning of the year[23] - The total liabilities and equity amounted to CNY 1,867,402,037.41, up from CNY 1,849,235,259.72, indicating a growth of 1.0%[24] Research and Development - Research and development expenses decreased by 40.57% compared to the same period last year, indicating a reduction in spending[12] - Research and development expenses decreased to CNY 5,071,479.88 from CNY 8,532,915.11, a reduction of 40.5%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,894, with the largest shareholder holding 32.10% of the shares[15] - The company held its first temporary shareholders' meeting on March 10, 2023, successfully completing the election of the fifth board of directors and supervisory board[19] Other Notable Events - The subsidiary, Guizhou Laya Technology Co., Ltd., received medical device registration and production licenses for its blood glucose meter and test strips[18] - The company did not undergo an audit for the first quarter report, indicating that the figures are unaudited[31]